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Increased postoperative cardiac troponin (cTn) independently predicts short-term mortality.
Previous studies suggest that preoperative cTn also predicts major adverse cardiovascular
events (MACE) and mortality after noncardiac surgery. The value of preoperative and peri-
operative changes in cTn as a prognostic tool for adverse outcomes has been sparsely
investigated.
Methods and findings
A systematic review and meta-analysis of the prognostic value of cTns for adverse outcome
was conducted. Adverse outcome was defined as short-term (in-hospital or <30 days) and
long-term (>30 days) MACE and/or all-cause mortality, in adult patients undergoing noncar-
diac surgery. The study protocol (CRD42018094773) was registered with an international
prospective register of systematic reviews (PROSPERO). Preoperative cTn was a predictor
of short- (OR 4.3, 95% CI 2.9–6.5, p<0.001, adjusted OR 5.87, 95% CI 3.24–10.65,
p<0.001) and long-term adverse outcome (OR 4.2, 95% CI 1.0–17.3, p = 0.05, adjusted HR
2.0, 95% CI 1.4–3.0, p<0.001). Perioperative change in cTn was a predictor of short-term
adverse outcome (OR 10.1, 95% CI 3.2–32.3, p<0.001). It was not possible to conduct
pooled analyses for adjusted estimates of perioperative change in cTn as predictor of short-
(a single study identified) and long-term (no studies identified) adverse outcome. Further, it
was not possible to conduct pooled analyses for unadjusted estimates of perioperative
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change in cTn as predictor of long-term adverse outcome, since only one study was identi-
fied. Bivariate analysis of sensitivities and specificities were performed, and overall prognos-
tic performance was summarized using summary receiver operating characteristic (SROC)
curves. The pooled sensitivity and specificity for preoperative cTn and short-term adverse
outcome was 0.43 and 0.86 respectively (area under the SROC curve of 0.68). There were
insufficient studies to construct SROCs for perioperative changes in cTn and for long-term
adverse outcome.
Conclusion
Our study indicates that although preoperative cTn and perioperative change in cTn might
be valuable predictors of MACE and/or all-cause mortality in adult noncardiac surgical
patients, its overall prognostic performance remains uncertain. Future large, representative,




Cardiac morbidity and mortality are common complications [1, 2] to the large number of non-
cardiac surgeries carried out on adult patients every year [3, 4]. Current guidelines recommend
the use of the RCRI [2] and NSQIP-MICA [5] for cardiovascular risk stratification in noncar-
diac surgery [6–9]. The discriminative ability and generalizability of these indices have been
questioned [5, 6, 10] and there is a need for new and, better tools to stratify patients according
to risk of perioperative cardiac morbidity and mortality. Cardiac troponin I and T (cTnI/T)
are cardiac specific proteins released by cardiomyocytes into the blood following injury to the
myocardium that may or may not be due to ischemia (e.g. severe sepsis) [11]. The prognostic
value of postoperative cTn has previously been investigated by large, multicenter prospective
studies [1, 12] and in two systematic reviews and meta-analyses [13, 14]. Guidelines now sug-
gest postoperative surveillance for myocardial injury in high-risk patients [6, 7, 9]. In contrast,
preoperative cTn and perioperative changes in cTn (i.e. change between pre- and postopera-
tive cTn) are still sparsely evaluated. The association between preoperative troponin levels and
short-term major adverse cardiovascular events (MACE) and mortality was demonstrated in a
recent meta-analysis [15]. However, data on long-term adverse outcome was limited in that
study. Changes in perioperative troponins are also relevant to investigate since they may pro-
vide an early indication of perioperative myocardial injury that is not reflected in preoperative
or postoperative values alone. As far as we are aware, the predictive value of perioperative
change in cTn has not been analyzed in a systematic review.
Although meta-analyses may summarize the prognostic value of biomarkers, the relation-
ship between sensitivity and specificity is not considered and there is a need to assess the over-
all prognostic performance of the pooled results. This may be best done by considering cTns
as a test of diagnostic accuracy.
Objectives
The objective of our study was two-fold:
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decision to publish, or preparation of the
manuscript.
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Firstly, to systematically review and conduct meta-analyses to answer the following ques-
tions: 1) Does preoperative cTn predict short- and long-term adverse outcome? 2) Do periop-
erative changes in cTn predict short- and long-term adverse outcome?
Secondly, we sought to analyze the overall prognostic performance of preoperative cTn and
perioperative changes in cTn. The adverse outcome was short- (in-hospital or <30 days) and
long-term (>30 days) all-cause mortality and/or MACE in adult patients undergoing noncar-
diac surgery.
Methods
We adhered to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) statement [16] in conducting and reporting this systematic review. On the 23rd of
January 2016, we conducted two searches in the electronic databases, Medline via PubMed
and Embase via Ovid. No filters, with respect to year of publication or language, were used.
The following MeSH terms were used in the Medline search: ‘Troponin’, ‘Surgical Procedures,
Operative’/’surgery’/’Postoperative Complications’, ‘Cardiovascular Diseases’/’Mortality’/
’Death’, ‘Prognosis’/’Risk Assessment’/’Sensitivity and Specificity’, ‘Perioperative Care’/’Peri-
operative Period’ (S1 File). The search strategy was developed with the assistance of a librarian
at Lund University, Sweden. On the 23rd of June 2017, we conducted an updated search identi-
cal to the two searches mentioned, to identify papers published between 23rd of January 2016
to 23rd of June 2017. Two authors independently screened titles (MSC, CH or MSC, IJ),
abstracts and full-text articles (IJ, CH or IJ, MSC) in accordance with predefined eligibility cri-
teria. Differing opinions on whether to include or exclude full-text articles were resolved
through discussion by two authors (IJ, CH or IJ, MSC). If consensus could not be reached, a
third author (MSC or CH) reviewed the full-text article and made the final decision. Further-
more, the reference lists of the included studies [12, 17–35], in addition to three central reviews
[7, 36, 37] were screened to identify additional eligible studies. The study protocol
(CRD42018094773) was registered with an international prospective register of systematic
reviews (PROSPERO). (S2 File).
Eligibility criteria
Full-text articles were included in our qualitative analysis if they fulfilled the following:
Inclusion criteria. Population: Human adults, i.e.�18 years old.
Type of surgery: Non-cardiac surgery.
Type of study: All studies measuring cTn, pre- and/or pre- and postoperatively, investigat-
ing the association between preoperative cTn and outcome(s) and/or perioperative change
in cTn (i.e. change between pre- and postoperative cTn) and outcome(s).
Type of cardiac troponin: cTnT, cTnI, high-sensitivity cTnT (hs-cTnT), high-sensitivity
cTnI (hs-cTnI).
Outcome: All-cause mortality and/or MACE as defined by the original studies.
Effect measure: Unadjusted odds ratio (OR); adjusted OR (aOR); unadjusted risk ratio
(RR); adjusted RR (aRR); unadjusted hazard ratio (HR); adjusted HR (aHR); data available
to construct 2x2 contingency table; single p-values (i.e. if nothing else is given); relevant
quotes on association (i.e. if not stated in numbers, e.g. “the unadjusted association was not
statistically significant”).
Blood sampling: Up to 30 days prior to and after surgery.
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Exclusion criteria. Transplantation surgery.
Non-full text articles, not full report, case series, letters, brief reports.
Bias assessment
We used the Quality In Prognostic Studies (QUIPS) tool [38] to assess the risk of bias in the
individual, included studies. The QUIPS tool consists of six, separate bias domains: selection
bias; attrition bias; prognostic factor (i.e. cTn) measurement bias; outcome measurement bias
(i.e. eligible outcome); study confounding and finally, bias related to statistical analysis and
reporting. We further customized the tool to suit our study (S3 File). Importantly, for the
study confounder assessment we predefined six important, potential confounders: age [1];
RCRI score [2] (in any way it was adjusted for); pre-existing kidney disease [39] or injury;
peripheral vascular disease [1]; urgency of surgery [1]; and length of surgery [40]. For each of
the six domains the risk of bias was assessed as low, moderate or high. The bias assessment was
conducted independently by two authors (CH, MSC). Differing opinions were resolved
through discussion by the two authors.
Data extraction
The following data extraction was performed from the included full-text articles independently
by two authors into piloted forms:
Baseline data: First author, year of publication, study design, number of participating cen-
ters, study period, sample size (i.e. number of patients included in the statistical analysis),
type of surgery, risk of surgery [9, 41], urgency of surgery, mean or median age (if not
explicitly stated, we calculated it if possible), male proportion (if not explicitly stated, we
calculated it if possible).
Troponin data: cTn type, assay manufacturer, timing and frequency of cTn sampling (i.e.
for the cTn included as prognostic factor in the statistical analysis), prognostic cTn cut-off
concentration (for conventional cTn we converted all units to μg/L).
Outcome data: Length of follow-up for eligible outcome (i.e. adverse outcome), proportion
between number of patients lost to follow-up and number of patients at study baseline, eli-
gible outcome, proportion of sample size with adverse outcome, proportion of patients with
elevated cTn with adverse outcome, proportion of patients with non-elevated cTn with
adverse outcome, data to reconstruct 2x2 contingency table (S1 Table), sensitivity and spec-
ificity (if not explicitly stated, we calculated it if possible), eligible effect measure with 95%
CI and p-value (if reported), variables adjusted for in multivariate analysis (if applicable).
We extracted all eligible data reported, e.g. if a study reported more than one eligible effect
size, we extracted all eligible effect sizes.
Statistical analysis
Meta-analyses were subgrouped according to: type of predictor (i.e. preoperative cTn or periop-
erative change in cTn), type of effect measure (e.g. OR or HR), whether the effect size was unad-
justed or adjusted and lastly timing of adverse outcome. Furthermore, if possible we conducted
subgroup meta-analysis according to the type of troponin assay (i.e. cTnT/cTnI or hs-TnT).
Regarding timing of adverse outcome, we adopted a limit of 30 days or less, including in-
Perioperative cardiac troponin prognostic performance
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hospital adverse outcome, for short-term adverse outcome and more than 30 days for long-
term adverse outcome. If one study had more than one effect size eligible for the same sub
group meta-analysis, the effect size with the most outcome events was chosen. If there was no
difference in number of outcome events we chose the effect size reported in the abstract of the
study. Unadjusted OR reported in the meta-analyses were calculated from 2x2 contingency
tables when possible, even for studies that reported a corresponding unadjusted OR. If the
study, on the other hand, reported an unadjusted OR, but not data enough to reconstruct a 2x2
contingency table, the OR reported in the study was used in the pooled analysis. We pooled
effect sizes using the DerSimonian and Laird random effects model [42]. All p-values were two-
sided and a value<0.05 was considered statistically significant. In seven of the eight meta-analy-
ses the generic inverse variance method was used, which required the standard error of the nat-
ural logarithm of the effect size calculated according to Woolf’s formula [43]. We calculated the
I2 statistic and Cochran’s Q (reported with a p-value) to assess heterogeneity between studies.
An I2 value more than 25 per cent and a p-value less than 0.10 was considered to represent sig-
nificant heterogeneity [44]. Analyses were performed using MedCalc Statistical Software ver-
sion 18.5.0 and 18.11.3 (MedCalc Software bvba, Ostend, Belgium, https://www.medcalc.org;
2016). Sensitivity and specificities for each study were summarized in forest plots, demonstrat-
ing between-study variation. The sensitivities and specificities were pooled and the mean was
estimates by bivariate modelling [45]. In order to evaluate the overall prognostic performance
of cTn, we generated summary receiver operating characteristic (SROC) curves (R software,
v3.5.0).
Results
Our search strategy identified a total of 1795 records. After an initial screening of titles and
abstracts, 1739 records were eliminated, of which 394 were duplicates. Fifty-six full-text articles
were assessed for eligibility. Twenty eligible studies [12, 17–35] were identified. (Fig 1). Nine-
teen [17–35] studies were included addressing preoperative cTn and three studies [12, 26, 29]
addressing perioperative change in cTn as prognostic factor. Notably Gillman et al. [29] and
Nagele et al. [26] were included in both categories.
Twelve studies provided adjusted estimates [12, 19, 23–29, 31, 34, 35]. In the remaining
studies only unadjusted estimates were provided. We wrote to individual authors requesting
additional data in order to obtain original data to conduct our own adjusted analyses but
received inadequate responses, consequently this option was not further explored. Results are
therefore presented for adjusted and unadjusted analyses for preoperative and perioperative
changes in cTns respectively.
Bias assessment
Table 1 provides an overall picture of the methodological quality of the studies as evaluated by
the QUIPS tool [38]. A majority of the studies had moderate or high risk of selection bias [17,
19–21, 23, 25–28, 32, 34, 35], confounding [12, 17–22, 24–29, 31–35] and bias related to statis-
tical analysis and presentation of results [17–23, 26, 27, 29, 32–35]. Furthermore, most of the
studies evaluating adverse outcome other than ‘mortality’ had moderate risk of outcome mea-
surement bias [17–19, 23, 25, 27, 29, 31, 33].
Preoperative cardiac troponin
Study and patient related characteristics. Nineteen studies assessed preoperative cTn
with a total sample size of 13386 (range 33 to 4575) [17–35]. A majority of the studies were
prospective cohort studies performed at a single centre [17–26, 28–31, 33, 35]. The studies
Perioperative cardiac troponin prognostic performance
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included patients undergoing a wide range of non-cardiac surgeries, the majority of which
were intermediate- or high- risk procedures. Six of the studies specifically included only
patients with cardiovascular disease or patients at risk of it [17, 22, 26–28, 35]. One study [19]
included only patients with ASA class III to IV. (Table 2).
Cardiac troponin related characteristics. Conventional cTnI or cTnT was used in most
of the studies, whereas hs-cTnT was used in the remaining studies [22, 26, 27, 29, 33, 35]. The
Fig 1. Flow diagram of study identification and selection.
https://doi.org/10.1371/journal.pone.0215094.g001
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range of prognostic cut-off concentration for conventional cTnT and cTnI was 0.03 μg/L to
0.2 μg/L and 0.05 μg/L to 0.5 μg/L, respectively. For hs-cTnT the range was 14 ng/L to 17.8 ng/






















cTn related to the







outcome related to the




effect of cTn is
distorted by another
factor that is related to









H L L M H M
Gibson,
2006 [18]
L L M M H M
Oscarsson,
2009 [19]
M H L M H H
Chong,
2010 [20]
M L L L H M
Talsnes,
2011[21]
M L L L H H
Alcock,
2012 [22]
L L L L H M
Biccard,
2012 [23]
H H M M L H
Degos,
2012 [24]
L L L L H L
Chong,
2013 [25]
M M M M H L
Nagele,
2013 [26]
H L L L M M
Weber,
2013 [27]
H L L M M M
Zheng,
2013 [28]
M L M L M L
Gillmann,
2014 [29]
L L L M M M
Hietala,
2014 [30]
L L L L L L
Ma,
2015 [31]
L L L M M L
Maile,
2016 [32]
H L M L M M
Thomas,
2016 [33]
L L L M H M
Zimmerman,
2016 [34]
H L L L H M
Devereaux,
2017 [12]
L L L L M L
Kopec,
2017 [35]
H L L L M M
cTn = Cardiac troponin. H = High risk of bias. M = Moderate risk of bias. L = Low risk of bias. t = We defined the following factors as important, potential confounders:
age; Revised Cardiac Risk Index Score; pre-existing kidney disease or injury; peripheral vascular disease; urgency of surgery; length of surgery.
https://doi.org/10.1371/journal.pone.0215094.t001
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Table 2. Study and patient related characteristics of included studies.
Studies assessing the association between preoperative cardiac troponin and adverse outcome
First author,
Year
Study design Study period Sample
size§
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L. Two studies did not quantify their cut-off concentrations [18, 28]. The timing of preopera-
tive blood sampling ranged from a few days to hours before surgery, and was not specified in
six studies [17, 20, 25, 29, 33, 34]. Assay characteristics, cut-off concentrations and timing of
cTn sampling are summarized in S2 Table.
Ability of preoperative cardiac troponin to predict short-term adverse outcome—unad-
justed analysis. The proportion of patients who had short-term adverse outcome varied
from 3 to 46 per cent. The sensitivity and specificity for preoperative cTn to predict short-term
adverse outcome ranged from 9 to 70 and 60 to 99 per cent, respectively. (Table 3). Fig 2
reports the meta-analysis of the twelve studies [17, 22, 23, 25–29, 32–35] for which we could
obtain an OR for preoperative cTn to predict short-term adverse outcome. The total sample
size was 9328 (range 85 to 4575). Preoperative cTn was a significant, unadjusted predictor of
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Studies assessing the association between perioperative change in cardiac troponin and adverse outcome
First author,
Year
Study design Study period Sample
size
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urology, major gynecology, major orthopedic, major
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AAA = Abdominal aortic aneurysm. NR = Not reported. RCT = Randomized controlled trial. SD = Standard deviation.
§ = Patients included in eligible effect measure analysis.
† = Not explicitly stated, calculated by authors.
†† = Not explicitly stated, concluded by authors.
• = Median age.
���Discrepancy between reported figures at different locations in the article.
https://doi.org/10.1371/journal.pone.0215094.t002
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Table 3. Association between cardiac troponin and adverse outcome.
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heterogeneity between the studies (I2 = 75%, p<0.0001). Subgroup meta-analyses, according
to the type of troponin assay (i.e. conventional cTnT/cTnI or hs-cTnT), showed that cTn was
clearly predictive in both subgroups of studies (S1 and S2 Figs).
Ability of preoperative cardiac troponin to predict short-term adverse outcome—
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ACS = Acute coronary syndrome. AF = Atrial fibrillation. AMI = Acute myocardial infarction. ASA = American Society of Anesthesiologists. BMI = Body mass index.
BNP = Brain natriuretic peptide. CAD = Coronary artery disease. CHF = Congestive heart failure. CK-MB = Creatine kinase-Muscle/brain. cMInj = Combined
myocardial injury. COPD = Chronic obstructive pulmonary disease. CPR = Cardio-pulmonary resuscitation. CRP = C reactive protein. cTn = Cardiac troponin.
cTnI = Cardiac troponin I. cTnT = Cardiac troponin T. ECG = Electrocardiogram. eGFR = Estimated glomerular filtration rate. GCS = Glasgow coma scale. h = Hours.
hs-cTnT = High-sensitivity cardiac troponin T. HR = Hazard ratio. ICU = Intensive care unit. IHD = Ischemic heart disease. MACE = Major adverse cardiac event.
MI = Myocardial infarction. MINS = Myocardial injury after non-cardiac surgery. NA = Not applicable. No. = Number. NR = Not reported. NYHA = New York Heart
Association. OR = Odds ratio. PVD = Peripheral vascular disease. RCRI = Revised Cardiac Risk Index. URL = 99th percentile upper reference limit decided by assay
manufacturer. VF = Ventricular fibrillation.
§ = Patients included in eligible effect measure analyses.
§§ = Patients at study baseline.
† = Not explicitly stated, calculated by authors.
†† = Not explicitly stated, concluded by authors.
��� = Discrepancy between reported figures at different locations in the article.
Δ = Change.
˚ = Data reported in study.
˚˚ = Figures used in the meta-analyses, yielded from reconstructing 2x2 contingency tables.
https://doi.org/10.1371/journal.pone.0215094.t003
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35] for which we could obtain an aOR for preoperative cTn to predict short-term adverse out-
come. The total sample size was 4840 (range 186 to 2519). Preoperative cTn was an indepen-
dent predictor of short-term adverse outcome (aOR 5.87, 95% CI 3.24–10.65, p<0.001),
however there was substantial heterogeneity between studies (I2 = 57%, p = 0.03). There was
great variability with respect to number and type of variables adjusted for. All studies adjusted
for cardiovascular comorbidity, however only two of the studies [19, 23] adjusted for RCRI.
(Table 3). Subgroup meta-analysis, according to the type of troponin assay showed that con-
ventional cTn was clearly predictive of short-term adverse outcome (S3 Fig). It was not possi-
ble to conduct subgroup meta-analysis for hs-cTnT since only one study [35] used this type of
assay.
Ability of preoperative cardiac troponin to predict long-term adverse outcome—unad-
justed analysis. The proportion of patients who had long-term adverse outcomes varied
from 13 to 39 per cent. The sensitivity and specificity for preoperative cTn to predict long-
term adverse outcome ranged from 23 to 48 and 60 to 100 per cent, respectively. (Table 3). Fig
Fig 2. Unadjusted odds ratios for elevation in preoperative cTn to predict short-term adverse outcome. Forest plot showing the individual
and pooled unadjusted odds ratios from the included studies. cTn = Cardiac troponin. CI = Confidence interval. # = Number of.
https://doi.org/10.1371/journal.pone.0215094.g002
Fig 3. Adjusted odds ratios for elevation in preoperative cTn to predict short-term adverse outcome. Forest plot showing the
individual and pooled adjusted odds ratios from the included studies. cTn = Cardiac troponin. CI = Confidence interval. # =
Number of.
https://doi.org/10.1371/journal.pone.0215094.g003
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4 reports the meta-analysis of the four studies [18, 20, 21, 24] for which we could obtain an OR
for preoperative cTn to predict long-term adverse outcome. The total sample size was less than
600 (one study [21] did not report sample size). Preoperative cTn was a significant, unadjusted
predictor of long-term adverse outcome (OR 4.2, 95% CI 1.0–17.3, p = 0.05), however there
was substantial heterogeneity between studies (I2 = 73%, p = 0.01). (Table 3). All four studies
used conventional cTn, consequently it was not applicable to conduct subgroup meta-analyses
according to the type of troponin assay.
Ability of preoperative cardiac troponin to predict long-term adverse outcome—
adjusted analysis. Fig 5 reports the meta-analysis of the two studies [26, 30] for which we
could obtain an aHR for preoperative cTn to predict long-term adverse outcome. The total
sample size was 808. Preoperative cTn was an independent predictor of long-term adverse out-
come (adjusted HR 2.0, 95% CI 1.4–3.0, p<0.001), heterogeneity was low (I2 = 0%, p = 0.79).
There was variability with respect to type of variables adjusted for. Both studies adjusted for
cardiovascular comorbidity, however only one of the studies [30] adjusted for RCRI. (Table 3).
As there were only two studies investigating the association, it was not possible to conduct fur-
ther subgroup meta-analyses according to the type of troponin assay.
Perioperative change in cardiac troponin
Study and patient related characteristics. Three studies with a total sample size was 8920
(range 455 to 7857) reported data for changes in cTn. All three studies [12, 26, 29] were pro-
spective cohort studies, one of them performed as a large, international multicenter study [12].
The studies included patients undergoing a wide range of surgical procedures with varying
risk. (Table 2).
Cardiac troponin related characteristics. All three studies [12, 26, 29] evaluated changes
in hs-cTnT (i.e. change between pre- and postoperative cTn). The cut-off for absolute change
in hs-cTnT ranged from 6.3 ng/L to 14 ng/L. Most of the preoperative blood sampling was
conducted on the day of surgery. The postoperative blood was sampled serially until day three
after surgery in two of the studies [12, 26], whereas one study [29] sampled blood only once,
24 hours after surgery. (S2 Table).
Ability of perioperative change in cardiac troponin to predict short-term adverse out-
come—unadjusted analysis. The proportion of patients who had short-term adverse out-
come varied from 1 to 9 per cent. The sensitivity and specificity for a change in hs-cTnT to
Fig 4. Unadjusted odds ratios for elevation in preoperative cTn to predict long-term adverse outcome. Forest plot showing the
individual and pooled unadjusted odds ratios from the included studies. cTn = Cardiac troponin. CI = Confidence interval. # = Number of.
https://doi.org/10.1371/journal.pone.0215094.g004
Perioperative cardiac troponin prognostic performance
PLOS ONE | https://doi.org/10.1371/journal.pone.0215094 April 22, 2019 14 / 23
predict short-term adverse outcome ranged from 76 to 83 and 66 to 80 per cent, respectively.
Fig 6 reports the meta-analysis of the two studies [12, 29] for which we could obtain an unad-
justed OR for an absolute change in hs-cTnT to predict short-term adverse outcome. The total
sample size was 8312. An absolute change in hs-cTnT was a significant, unadjusted predictor
of short-term adverse outcome (unadjusted OR 10.1, 95% CI 3.2–32.3, p<0.001), however
there was a substantial heterogeneity (I2 = 83%, p = 0.02).
Ability of perioperative change in cardiac troponin to predict short-term adverse out-
come—adjusted analysis. Devereux et al. [12] demonstrated that an absolute change in hs-
cTnT was an independent predictor (aHR 4.53, 95% CI 2.77–7.39, p<0.001) of short-term
adverse outcome. The authors adjusted for preoperative and surgical variables, previously
associated with 30-day mortality [46]. In addition, Gillmann et al. [29] stated that an absolute
change in hs-cTnT was independently associated with short-term adverse outcome, however
the actual effect size was not reported. (Table 3).
Ability of perioperative change in cardiac troponin to predict long-term adverse out-
come—unadjusted analysis. Only one study reported the association between change in cTn
and long-term adverse outcome [26]. An absolute change in hs-cTnT was associated with
long-term adverse outcome (HR 1.58 (95% CI, 0.95–2.64, p = 0.078). There were no studies
reporting adjusted effect sizes for long-term adverse outcome. (Table 3).
Prognostic performance of preoperative cardiac troponin to predict short-term adverse
outcome. A forest plot of the sensitivities and specificities for preoperative cTn to predict
short-term adverse outcome [17, 23, 26–29, 32–35] demonstrated significant heterogeneity (χ2
= 80.1, p<0.001 and χ2 = 723.7, p<0.001 respectively) between studies. (S4 Fig). A summary
ROC curve returned an AUC of 0.68 with a large prediction region. The pooled sensitivities
and specificities were 0.43 (CI 0.29–0.58) and 0.85 (CI 0.73–0.94) respectively. (Fig 7).
There were only three studies of preoperative cTn and long-term adverse outcome [18, 20,
24], and only two studies of changes in cTn and any adverse outcome [12, 29]. Forest plots of
sensitivity and specificities and SROC curves were therefore not generated for these studies.
Discussion
This meta-analysis suggests that preoperative cTn predicts adverse outcome defined as MACE
and/or all-cause mortality in adult noncardiac surgical patients. The effect was best demon-
strated for short-term adverse outcome, and was sustained in adjusted analyses. In addition,
pooled estimates show that cTn predicts adverse outcome, regardless of follow-up time, adjust-
ment for confounders, and whether cTn was considered as preoperative values or periopera-
tive changes. Additional subgroup meta-analysis, according to the type of troponin assay
showed that preoperative cTn was clearly predictive of short-term adverse outcome in both
subgroups of studies (i.e. conventional cTnT/cTnT and hs-cTnT). This is in line with the
recent study by Gualandro et al. [47]. Despite this demonstrated effect, analysis of the prognos-
tic performance of preoperative cTns was poor for short-term adverse outcome. Thus,
although this meta-analysis suggests that preoperative cTn predicts adverse outcome, SROC
analysis reveals that the prognostic performance of preoperative cTn is poor. For long-term
adverse outcome and perioperative change in cTn we were unable to adequately evaluate the
prognostic performance.
Increased postoperative cTn is associated with increased risk of adverse events and guide-
lines now suggest postoperative surveillance for myocardial injury in high-risk patients [6, 7, 9].
The present study indicates that this might also apply to preoperative measurements although
the evidence is less strong. Our findings support the recent meta-analysis by Shen et al. [15]
demonstrating independent associations between increased preoperative cTn and short-term
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MACE and mortality. We add to those findings by including studies for long-term adverse out-
come, where unadjusted and adjusted analyses demonstrated a relationship with cTn.
Since many patients have elevations in preoperative cTn, we also investigated the predictive
value of perioperative changes. This is relevant since perioperative changes in cTns may imply
differences in outcomes and perioperative management. Although this meta-analysis indicates
that a perioperative change in cTn might have a prognostic value for short-term adverse out-
come after noncardiac surgery, these were unadjusted estimates and we were not able to per-
form a meta-analysis with a change in cTn as adjusted predictor. Furthermore, there was
substantial heterogeneity and the findings were based on only two studies. Thus, were we
unable to support or refute the findings of Gillmann et al. [29] where perioperative changes in
cTn improved the reclassification of patients with non-events. Lastly, a change in cTn might
have a prognostic value for long-term adverse outcome, however we were only able to identify
one, relatively small study investigating this association. In a recent study not included within
the time frame for our meta-analysis, Puelacher et al. [48] showed that an absolute change in
Fig 5. Adjusted hazard ratios for elevation in preoperative cTn to predict long-term adverse outcome. Forest plot showing the
individual and pooled adjusted hazard ratios from the included studies. cTn = Cardiac troponin. CI = Confidence interval. # = Number of.
https://doi.org/10.1371/journal.pone.0215094.g005
Fig 6. Unadjusted odds ratios for an absolute perioperative change in cTn to predict short-term adverse outcome. Forest plot showing
the individual and pooled unadjusted odds ratios from the included studies. cTn = Cardiac troponin. CI = Confidence interval. # = Number
of.
https://doi.org/10.1371/journal.pone.0215094.g006
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perioperative cTn of� 14 ng/L was significantly associated with both short- and long-term
adverse outcome after noncardiac surgery, even after adjustment for other confounders.
Although the meta-analysis demonstrated the association between cTn and adverse out-
come, these were derived from multivariable analyses that only variably adjusted for relevant
confounders. To determine whether predictors identified in multivariable analyses signifi-
cantly improve preoperative risk prediction compared to current risk scores, the net reclassifi-
cation index (NRI) may be used. The net reclassification index objectively evaluates the
prognostic performance of a risk predictor when added on to current risk prediction methods,
calculated as the difference between the proportion of patients correctly and incorrectly reclas-
sified according to the study outcome. We identified only three studies reporting the NRI.
Generally, an improvement in NRI was seen using preoperative [23, 26, 29] or perioperative
changes in cTns [29]. However, a potential for misclassification was also demonstrated by
Fig 7. Summary receiver operating characteristic (SROC) curve for prognostic performance of preoperative cTn to
predict short-term adverse outcome. Filled dots = observed data. Unfilled dot = pooled sensitivity (0.43 [CI 0.29–0.58]) and
specificity (0.85 [CI 0.73–0.94]). Black curve = SROC curve (AUC = 0.68). Black-lined region = 95% confidence region.
Dashed-lined region = 95% prediction region.
https://doi.org/10.1371/journal.pone.0215094.g007
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misclassifying patients with events into a low-risk group [23, 29]. Regarding the prognostic
performance of preoperative cTn for short-term adverse outcome, our results indicate that it
has only moderate predictive ability (AUC for SROC curve 0.68). Importantly the lower
boundary of the 95% prediction region approaching the line of equality, indicating that test
performance is poor.
Strengths and limitations
Strengths of our study include conducting and reporting the study in accordance with the
PRISMA statement [16], the comprehensive and reproducible search strategy including
reviewing relevant reference lists and lastly conducting eligibility decisions, data extraction
and bias assessment in duplicate. We recognize that our study has several limitations. Our eli-
gibility criteria were liberal to ensure inclusion of studies in a heterogeneous field. This is
reflected in the heterogeneity across the studies, complicating the interpretation of our find-
ings. On the other hand, it is our appraisal that with stricter eligibility criteria we would have
excluded several important individual studies, consequently missing out on valuable informa-
tion. Regarding preoperative cTn, the most important limitation was the substantial heteroge-
neity across the studies, where important differences exist regarding type of surgery, assay
manufacturer, timing of cTn sampling, type of cTn, prognostic cut-off concentration and out-
come. There were also significant methodological limitations in the included studies. In the
unadjusted meta-analysis for short-term adverse outcome, one study constituting fifty per cent
of the total sample size was a retrospective study [32], with a high-risk of selection bias. Forty
per cent of the studies adjusted for more than one variable per ten outcome events [19, 34, 35],
creating a risk of unreliable estimates [49]. Yet, a majority of the studies did not adjust for
important potential confounders, e.g. the RCRI, reducing the reliability in assessing the inde-
pendent prognostic value of preoperative cTn. For perioperative changes in cTn, the most
essential limitation was that the findings were based on one study only [12], although we
acknowledge that this was a rigorously conducted multicenter international study. Moreover,
perioperative changes were only considered for a subgroup of patients. The recently published
study by Puelacher et al. [48] however supports the finding by Devereaux et al. [12] that peri-
operative change in cTn is associated with short-term adverse outcome.
The relationship between sensitivity and specificity is essential in evaluating the prognostic
performance of a test. In our study, since different criteria (e.g. type of troponin assay, cut-offs,
patient populations) have been used, there will be different relationships between sensitivity
and specificity across the studies. As sensitivity increases, specificity will generally drop
(threshold effect). Thus, averaging sensitivities and specificities across may not reflect the over-
all accuracy of the test, and extremes of threshold criteria can cause inaccurate interpretations
of the pooled results. We used the SROC curve as way of overcoming this problem. Our study
demonstrated only an ‘acceptable’ AUC with a large prediction region indicating a heterogene-
ity in the underlying studies. However, there are also limitations relating to the SROC analysis
itself. For example, although the estimates are weighted, there is a bias towards tests with lower
diagnostic accuracy. Further, primary studies are assumed to be random samples of the larger
overall ‘SROC population’, and that differences in results are due to random error [50].
Regarding applicability of our findings, it should be taken into account that only one [12]
of the included studies fully covered a broad spectrum of ‘adult patients undergoing non- car-
diac surgery’ when considering the following as ‘broad spectrum’: wide range of age; equal sex
proportion; wide range of non-cardiac surgery; all risks of surgery; both elective and emergent
surgery and no specific risk factors or comorbidities in inclusion criteria. The applicability is
especially relevant for long-term outcome, since these findings were based on few studies.
Perioperative cardiac troponin prognostic performance
PLOS ONE | https://doi.org/10.1371/journal.pone.0215094 April 22, 2019 18 / 23
Implications for research and practice
Is preoperative cTn a good screening tool for increased mortality and MACE after noncardiac
surgery? Although conventional meta-analyses of risk estimates support the prognostic value
of preoperative, and to a lesser extent, perioperative changes in cTn, a meta-analysis of the sen-
sitivities and specificities for preoperative cTn suggest that prognostic performance is still
inadequate. However, the summary statistic was limited by differences in assays, cutoffs, study
populations and outcomes, limiting their interpretation. To potentially improve our under-
standing, we suggest that future studies use the current gold standard for assays, hs-cTn. We
also suggest measurement of both pre- and postoperative levels [11], with evaluation of con-
founding factors to help elucidate the meaning of pre- and perioperative changes in troponin
levels. Furthermore, we suggest investigation of whether perioperative hs-cTn alone or in a
panel of other risk factors (e.g. other biomarkers and clinical factors) provides better risk strati-
fication compared to the current golden standard [2, 5]. In this regard, the net classification
index that attempts to quantify how well a new model reclassifies subjects to the correct group
may be a useful analysis. This is the subject of an ongoing study (NCT03436238). If the prog-
nostic value of preoperative cTn and perioperative changes in cTns are confirmed, targeted
interventions based on cTn should be evaluated in high-quality, randomized controlled trials.
To our knowledge, there are currently no such published studies. A knowledge of the mecha-
nism behind poor postoperative outcomes would help in designing these studies and is the
subject of one ongoing prospective trial (NCT03317561).
Conclusion
Our study indicates that although preoperative cTn and perioperative change in cTn might be
valuable predictors of MACE and/or all-cause mortality in adult noncardiac surgical patients,
its overall prognostic performance remains uncertain. Future large, representative, high-qual-
ity studies are needed to establish the potential role of cTns in perioperative cardiac risk
stratification.
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